ADURO BIOTECH INC. news, videos and press releases
For more news please use our advanced search feature.
ADURO BIOTECH INC. - More news...
ADURO BIOTECH INC. - More news...
- Aduro BioTech, Inc. - ADRO Stock Chart Technical Analysis for 02-07-2020
- Aduro BioTech, Inc. - ADRO Stock Chart Technical Analysis for 02-03-2020
- Aduro BioTech, Inc. - ADRO Stock Chart Technical Analysis for 01-31-2020
- Aduro BioTech, Inc. - ADRO Stock Chart Technical Analysis for 12-19-18
- New Research: Key Drivers of Growth for Shutterfly, Aegion, Columbia Property Trust, Aduro Biotech, IQVIA, and Intelsat S.A — Factors of Influence, Major Initiatives and Sustained Production
- Aduro BioTech
- Aduro Biotech Announces Appointment of Leading Immunotherapy and Oncology Experts to Scientific Advisory Board
- Aduro Biotech Enters into Exclusive License Agreement for Proprietary Neoantigen Identification Technology
- Aduro Biotech Announces Clinical Collaboration with Merck to Evaluate the Combination of Aduro’s CRS-207 with Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Gastric Cancer
- Aduro Biotech to Present at the 35th Annual J.P. Morgan Healthcare Conference
- Aduro Biotech Europe’s Hans van Eenennaam, Ph.D. and John Dulos, Ph.D. Honored with the Intellectual Property Owners Education Foundation’s 43rd Inventor of the Year Award for Contributions in the Discovery of KEYTRUDA® (pembrolizumab)
- Aduro Biotech Announces Anti-CD27 Agonist, an Investigational Anti-Cancer Immunotherapy, Advancing in Collaboration with MSD
- Aduro Biotech Presents Preclinical Data Supporting Clinical Development of its Anti-APRIL Antibody, BION-1301, for the Treatment of Multiple Myeloma
- Partial Clinical Hold Lifted and Enrollment Resumes for Aduro Biotech LADD Clinical Trials
- Aduro Biotech Highlights Positive Clinical Results from Second Cohort of Phase 1b Mesothelioma Clinical Trial
- Aduro Biotech’s Personalized LADD Therapy Featured in an Oral Presentation at SITC’s New Cancer Immunotherapy Agents in Development Program
- Aduro Biotech Presents Preclinical Data Demonstrating Acute and Systemic Immune Activation through STING Pathway Stimulation with ADU-S100
- Aduro Biotech Reports Third Quarter 2016 Financial Results
- Aduro Biotech Reports Partial Clinical Hold to Pause Enrollment in LADD Trials
- Aduro Biotech to Host Conference Call